Boron neutron capture therapy of brain tumors: Clinical trials at the Finnish facility using boronophenylalanine

Heikki Joensuu, Leena Kankaanranta, Tiina Seppälä, Iiro Auterinen, Merja Kallio, Martti Kulvik, Juha Laakso, Jyrki Vähätalo, Mika Kortesniemi, Petri Kotiluoto, Tom Serén, Johanna Karila, Antii Brander, Eija Järviluoma, Päivi Ryynänen, Anders Paetau, Inkeri Ruokonen, Heikki Minn, Mikko Tenhunen, Juha JääskeläinenMarkus Färkkilä, Sauli Savolainen

    Research output: Contribution to journalArticleScientificpeer-review

    134 Citations (Scopus)

    Abstract

    Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT within a context of a prospective clinical trial (protocol P-01). All patients underwent prior surgery, but none had received conventional radiotherapy or cancer chemotherapy before BNCT. BPA-fructose was given as 2-h infusion at BPA-dosages ranging from 290 to 400 mg/kg prior to neutron beam irradiation, which was given as a single fraction from two fields. The average planning target volume dose ranged from 30 to 61 Gy (W), and the average normal brain dose from 3 to 6 Gy (W). The treatment was generally well tolerated, and none of the patients have died during the first months following BNCT. The estimated 1-year overall survival is 61%. In another trial (protocol P-03), three patients with recurring or progressing glioblastoma following surgery and conventional cranial radiotherapy to 50-60 Gy, were treated with BPA-based BNCT using the BPA dosage of 290 mg/kg. The average planning target dose in these patients was 25-29 Gy (W), and the average whole brain dose 2-3 Gy (W). All three patients tolerated brain reirradiation with BNCT, and none died during the first three months following BNCT. We conclude that BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients. Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT.

    Original languageEnglish
    Pages (from-to)123-134
    Number of pages12
    JournalJournal of Neuro-Oncology
    Volume62
    Issue number1-2
    DOIs
    Publication statusPublished - 1 Mar 2003
    MoE publication typeA1 Journal article-refereed

    Fingerprint

    Boron Neutron Capture Therapy
    Brain Neoplasms
    Clinical Trials
    Glioblastoma
    Clinical Protocols
    Brain
    Radiotherapy
    Neutrons
    Fructose
    Photons
    Patient Selection
    Radiation

    Keywords

    • BNCT
    • Boron neutron capture therapy
    • Glioblastoma
    • Glioma
    • Neutron beam radiotherapy
    • Radiotherapy

    Cite this

    Joensuu, Heikki ; Kankaanranta, Leena ; Seppälä, Tiina ; Auterinen, Iiro ; Kallio, Merja ; Kulvik, Martti ; Laakso, Juha ; Vähätalo, Jyrki ; Kortesniemi, Mika ; Kotiluoto, Petri ; Serén, Tom ; Karila, Johanna ; Brander, Antii ; Järviluoma, Eija ; Ryynänen, Päivi ; Paetau, Anders ; Ruokonen, Inkeri ; Minn, Heikki ; Tenhunen, Mikko ; Jääskeläinen, Juha ; Färkkilä, Markus ; Savolainen, Sauli. / Boron neutron capture therapy of brain tumors : Clinical trials at the Finnish facility using boronophenylalanine. In: Journal of Neuro-Oncology. 2003 ; Vol. 62, No. 1-2. pp. 123-134.
    @article{d90cbbba23ff427da39584618a796a9d,
    title = "Boron neutron capture therapy of brain tumors: Clinical trials at the Finnish facility using boronophenylalanine",
    abstract = "Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT within a context of a prospective clinical trial (protocol P-01). All patients underwent prior surgery, but none had received conventional radiotherapy or cancer chemotherapy before BNCT. BPA-fructose was given as 2-h infusion at BPA-dosages ranging from 290 to 400 mg/kg prior to neutron beam irradiation, which was given as a single fraction from two fields. The average planning target volume dose ranged from 30 to 61 Gy (W), and the average normal brain dose from 3 to 6 Gy (W). The treatment was generally well tolerated, and none of the patients have died during the first months following BNCT. The estimated 1-year overall survival is 61{\%}. In another trial (protocol P-03), three patients with recurring or progressing glioblastoma following surgery and conventional cranial radiotherapy to 50-60 Gy, were treated with BPA-based BNCT using the BPA dosage of 290 mg/kg. The average planning target dose in these patients was 25-29 Gy (W), and the average whole brain dose 2-3 Gy (W). All three patients tolerated brain reirradiation with BNCT, and none died during the first three months following BNCT. We conclude that BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients. Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT.",
    keywords = "BNCT, Boron neutron capture therapy, Glioblastoma, Glioma, Neutron beam radiotherapy, Radiotherapy",
    author = "Heikki Joensuu and Leena Kankaanranta and Tiina Sepp{\"a}l{\"a} and Iiro Auterinen and Merja Kallio and Martti Kulvik and Juha Laakso and Jyrki V{\"a}h{\"a}talo and Mika Kortesniemi and Petri Kotiluoto and Tom Ser{\'e}n and Johanna Karila and Antii Brander and Eija J{\"a}rviluoma and P{\"a}ivi Ryyn{\"a}nen and Anders Paetau and Inkeri Ruokonen and Heikki Minn and Mikko Tenhunen and Juha J{\"a}{\"a}skel{\"a}inen and Markus F{\"a}rkkil{\"a} and Sauli Savolainen",
    year = "2003",
    month = "3",
    day = "1",
    doi = "10.1023/A:1023293006617",
    language = "English",
    volume = "62",
    pages = "123--134",
    journal = "Journal of Neuro-Oncology",
    issn = "0167-594X",
    publisher = "Kluwer Academic Publishers",
    number = "1-2",

    }

    Joensuu, H, Kankaanranta, L, Seppälä, T, Auterinen, I, Kallio, M, Kulvik, M, Laakso, J, Vähätalo, J, Kortesniemi, M, Kotiluoto, P, Serén, T, Karila, J, Brander, A, Järviluoma, E, Ryynänen, P, Paetau, A, Ruokonen, I, Minn, H, Tenhunen, M, Jääskeläinen, J, Färkkilä, M & Savolainen, S 2003, 'Boron neutron capture therapy of brain tumors: Clinical trials at the Finnish facility using boronophenylalanine', Journal of Neuro-Oncology, vol. 62, no. 1-2, pp. 123-134. https://doi.org/10.1023/A:1023293006617

    Boron neutron capture therapy of brain tumors : Clinical trials at the Finnish facility using boronophenylalanine. / Joensuu, Heikki; Kankaanranta, Leena; Seppälä, Tiina; Auterinen, Iiro; Kallio, Merja; Kulvik, Martti; Laakso, Juha; Vähätalo, Jyrki; Kortesniemi, Mika; Kotiluoto, Petri; Serén, Tom; Karila, Johanna; Brander, Antii; Järviluoma, Eija; Ryynänen, Päivi; Paetau, Anders; Ruokonen, Inkeri; Minn, Heikki; Tenhunen, Mikko; Jääskeläinen, Juha; Färkkilä, Markus; Savolainen, Sauli.

    In: Journal of Neuro-Oncology, Vol. 62, No. 1-2, 01.03.2003, p. 123-134.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Boron neutron capture therapy of brain tumors

    T2 - Clinical trials at the Finnish facility using boronophenylalanine

    AU - Joensuu, Heikki

    AU - Kankaanranta, Leena

    AU - Seppälä, Tiina

    AU - Auterinen, Iiro

    AU - Kallio, Merja

    AU - Kulvik, Martti

    AU - Laakso, Juha

    AU - Vähätalo, Jyrki

    AU - Kortesniemi, Mika

    AU - Kotiluoto, Petri

    AU - Serén, Tom

    AU - Karila, Johanna

    AU - Brander, Antii

    AU - Järviluoma, Eija

    AU - Ryynänen, Päivi

    AU - Paetau, Anders

    AU - Ruokonen, Inkeri

    AU - Minn, Heikki

    AU - Tenhunen, Mikko

    AU - Jääskeläinen, Juha

    AU - Färkkilä, Markus

    AU - Savolainen, Sauli

    PY - 2003/3/1

    Y1 - 2003/3/1

    N2 - Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT within a context of a prospective clinical trial (protocol P-01). All patients underwent prior surgery, but none had received conventional radiotherapy or cancer chemotherapy before BNCT. BPA-fructose was given as 2-h infusion at BPA-dosages ranging from 290 to 400 mg/kg prior to neutron beam irradiation, which was given as a single fraction from two fields. The average planning target volume dose ranged from 30 to 61 Gy (W), and the average normal brain dose from 3 to 6 Gy (W). The treatment was generally well tolerated, and none of the patients have died during the first months following BNCT. The estimated 1-year overall survival is 61%. In another trial (protocol P-03), three patients with recurring or progressing glioblastoma following surgery and conventional cranial radiotherapy to 50-60 Gy, were treated with BPA-based BNCT using the BPA dosage of 290 mg/kg. The average planning target dose in these patients was 25-29 Gy (W), and the average whole brain dose 2-3 Gy (W). All three patients tolerated brain reirradiation with BNCT, and none died during the first three months following BNCT. We conclude that BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients. Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT.

    AB - Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT within a context of a prospective clinical trial (protocol P-01). All patients underwent prior surgery, but none had received conventional radiotherapy or cancer chemotherapy before BNCT. BPA-fructose was given as 2-h infusion at BPA-dosages ranging from 290 to 400 mg/kg prior to neutron beam irradiation, which was given as a single fraction from two fields. The average planning target volume dose ranged from 30 to 61 Gy (W), and the average normal brain dose from 3 to 6 Gy (W). The treatment was generally well tolerated, and none of the patients have died during the first months following BNCT. The estimated 1-year overall survival is 61%. In another trial (protocol P-03), three patients with recurring or progressing glioblastoma following surgery and conventional cranial radiotherapy to 50-60 Gy, were treated with BPA-based BNCT using the BPA dosage of 290 mg/kg. The average planning target dose in these patients was 25-29 Gy (W), and the average whole brain dose 2-3 Gy (W). All three patients tolerated brain reirradiation with BNCT, and none died during the first three months following BNCT. We conclude that BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients. Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT.

    KW - BNCT

    KW - Boron neutron capture therapy

    KW - Glioblastoma

    KW - Glioma

    KW - Neutron beam radiotherapy

    KW - Radiotherapy

    UR - http://www.scopus.com/inward/record.url?scp=0038523780&partnerID=8YFLogxK

    U2 - 10.1023/A:1023293006617

    DO - 10.1023/A:1023293006617

    M3 - Article

    C2 - 12749708

    AN - SCOPUS:0038523780

    VL - 62

    SP - 123

    EP - 134

    JO - Journal of Neuro-Oncology

    JF - Journal of Neuro-Oncology

    SN - 0167-594X

    IS - 1-2

    ER -